Breaking Finance News

H.C. Wainwright disclosed Codexis (NASDAQ:CDXS), hiking its price target to $8.50 earlier today

Having a price of $7.85, Codexis (NASDAQ:CDXS) traded 17.16% higher on the day. With the last close up 51.64% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the same time period. CDXS has recorded a 50-day moving average of $6.08 and a 200-day moving average of $5.18. 613,903 shares of CDXS traded hands, up from an average trading volume of 165,878

Reporting a potential upside of 0.08%, H.C. Wainwright upped the price target of Codexis (NASDAQ:CDXS) to $8.50

Recent Performance Chart


Codexis has 52 week low of $3.60 and a 52 week high of $7.90 and has a market capitalization of $0.

Brief Synopsis On Codexis (NASDAQ:CDXS)

Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.